Aggressive Lymphomas
News
Team identifies 5 subtypes of DLBCL
New research has revealed 5 genetic subtypes of diffuse large B-cell lymphoma (DLBCL). Researchers identified a group of low-risk activated B-cell...
News
CHMP recommends approval for generic carmustine
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Carmustine Obvius, a...
Conference Coverage
Radioimmunoconjugate shows activity in NHL
CHICAGO—The radioimmunoconjugate 177Lu-NNV003 has demonstrated activity against non-Hodgkin lymphomas (NHLs). Experiments showed that 177Lu-...
Conference Coverage
CDK inhibitor synergizes with venetoclax in CLL
CHICAGO—Researchers have reported “strong synergy” between the CDK2/9 inhibitor CYC065 and the Bcl-2 inhibitor venetoclax in chronic lymphocytic...
News
FDA places partial hold on trials after secondary lymphoma
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
News
FDA places tazemetostat trials on partial hold
The hold has halted enrollment in US-based trials of tazemetostat, but study subjects who have not experienced disease progression may continue to...
News
Art education benefits blood cancer patients
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
Conference Coverage
Inhibitor outperforms rivals in leukemia, lymphoma
CHICAGO—Preclinical research suggests the pan-FLT3/pan-BTK inhibitor CG’806 is more effective than other kinase inhibitors in fighting certain...
Conference Coverage
Team uses iPSCs to create ‘universal’ CAR T cells
CHICAGO—Researchers have used induced pluripotent stem cells (iPSCs) to create a “universal” chimeric antigen receptor (CAR) T-cell therapy known...
From the Journals
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
News
Research reveals new subtypes of DLBCL
New research helps explain why some patients with diffuse large B-cell lymphoma (DLBCL) respond well to immunochemotherapy and others do not....